<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6677">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03020004</url>
  </required_header>
  <id_info>
    <org_study_id>ASC08201502</org_study_id>
    <nct_id>NCT03020004</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II</brief_title>
  <official_title>A Phase 2,Multicenter,Open-Label Study to Investigate the Efficacy, Safety and Pharmacokinetics of Ritonavir-boosted Danoprevir in Combination With Peg-IFN and RBV in Treatment-Naive Non-Cirrhotic Patients Who Have Chronic Hepatitis GT1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascletis Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascletis Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Efficacy, Safety and Pharmacokinetics of
      Ritonavir-boosted Danoprevir (ASC08) in Combination with Peg-IFN and RBV in Treatment-Naive
      Non-Cirrhotic Patients Who Have Chronic Hepatitis Genotype 1.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects with sustained virologic response (SVR12) 12 weeks post-treatment</measure>
    <time_frame>12 months</time_frame>
    <description>SVR12, defined as undetectable HCV RNA 12 weeks after the last day of study drug administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants permanently discontinuing study drug(s) due to an adverse event (AE)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Danoprevir,Ritonavir, Peg-IFN,RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a combination of Ritonavir-boosted Danoprevir 100mg/100mg BID, subcutaneous injection of weekly peginterferon alfa-2a at 180 mcg and oral Ribavirin (RBV)1000/1200 mg/day (bodyweight&lt;75/≥75 kg) for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danoprevir</intervention_name>
    <description>Danoprevir (DNV) 100mg tablet administered orally twice daily</description>
    <arm_group_label>Danoprevir,Ritonavir, Peg-IFN,RBV</arm_group_label>
    <other_name>ASC08</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>Ritonavir 100mg tablet administered orally twice daily</description>
    <arm_group_label>Danoprevir,Ritonavir, Peg-IFN,RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peginterferon alfa-2a</intervention_name>
    <description>PegIFN subcutaneous injection at 180 mcg weekly</description>
    <arm_group_label>Danoprevir,Ritonavir, Peg-IFN,RBV</arm_group_label>
    <other_name>PegIFN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin (RBV)</intervention_name>
    <description>Ribavirin (RBV)1000/1200 mg/day (bodyweight&lt;75/≥75 kg)</description>
    <arm_group_label>Danoprevir,Ritonavir, Peg-IFN,RBV</arm_group_label>
    <other_name>Ribasphere®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to provide written informed consent

          -  Chronic HCV infection (≥ 6 months) ;

          -  Positive HCV antibody

          -  Serum HCV RNA of ≥ 1 × 104 IU/mL

          -  Hepatitis C virus GT1

          -  Never received prior-treatment for HCV with interferon, RBV, or other direct-acting
             or host-targeting antivirals for HCV

          -  The liver biopsy methods in the protocol (non-cirrhosis is defined as: Metavir score
             ˂ 4), or as determined by Fibroscan defined as: ˂ 14.6 kPa. Patients who have not
             obtained a liver biopsy or Fibroscan in the last 1 years will have a study related
             Fibroscan performed in order to confirm the diagnosis

          -  Others as specified in the detailed protocol

        Exclusion Criteria:

          -  Patients with Fibroscan detection value &gt; 12.9 kPa, or histologic examination for
             liver cirrhosis patients

          -  Presence or history of non-hepatitis C chronic liver disease, including but not
             limited to, autoimmune hepatitis, α-1-antitrypsin deficiency, C282Y homozygous
             hemochromatosis, Wilson's disease, drug- or toxin-induced liver disease,
             alcohol-related liver disease, primary biliary cirrhosis, sclerosing cholangitis, and
             porphyria cutanea tarda causing liver pathology or requiring phlebotomy

          -  Patients with a history of liver cell cancer, screening before or screening suspected
             hepatocellular carcinoma (HCC) patients, or imaging studies found suspicious nodules,
             or AFP &gt; 50 ng/mL

          -  Positive hepatitis A antibody，positive hepatitis B surface antigen，syphilis antibody
             or HIV antibody at screening

          -  Others as specified in the detailed protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huoling Tang, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Ascletis Pharmaceuticals Co., Ltd.</affiliation>
  </overall_official>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 11, 2017</lastchanged_date>
  <firstreceived_date>January 5, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Danoprevir</keyword>
  <keyword>SVR12</keyword>
  <keyword>Chinese HCV G1</keyword>
  <keyword>non-cirrhotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Lactams</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
